J
Javier P. Gisbert
Researcher at Autonomous University of Madrid
Publications - 1076
Citations - 39753
Javier P. Gisbert is an academic researcher from Autonomous University of Madrid. The author has contributed to research in topics: Helicobacter pylori & Inflammatory bowel disease. The author has an hindex of 95, co-authored 990 publications receiving 33726 citations. Previous affiliations of Javier P. Gisbert include Services Hospital & University of Alcalá.
Papers
More filters
Journal ArticleDOI
Overall Incidence of Hepatosplenic T Cell Lymphoma in Patients With Inflammatory Bowel Disease on Thiopurines: A Meta-Analysis of Three Population Based Studies
David Kotlyar,Javier P. Gisbert,James D. Lewis,Colleen M. Brensinger,Laurent Beaugerie,Wojciech Blonski,Robert Hirten,María Chaparro,Manuel Van Domselaar,Gary R. Lichtenstein +9 more
TL;DR: In a recent systematic review of HSTCL in IBD, while incidence could not be estimated, the absolute risk was estimated at being 1:44,444 overall and 1:7404 in men under 35, and these estimates accord with calculated numbers needed to harm of 1:75,488 per year overall and 2:12,616 per year inMen under 36.
Journal ArticleDOI
Rescue Therapy with Furazolidone in Patients with at Least Five Eradication Treatment Failures and Multi-Resistant H. pylori infection.
Elena Resina,Javier P. Gisbert +1 more
TL;DR: In this article, a quadruple regimen with furazolidone (200 mg), amoxicillin, metronidazole, tetracycline, and esomeprazole (40 mg) was prescribed twice a day for 14 days.
Journal ArticleDOI
Enfermedades relacionadas con Helicobacter pylori: dispepsia, úlcera y cáncer gástrico
TL;DR: La erradicacion de H. pylori no favorece la aparicion de enfermedad por reflujo gastroesofagico ni empeora su curso, aunque parece haberse estabilizado en una cifra todavia relevante, y las resistencias antibioticas estan aumentando en diversos paises.
Journal ArticleDOI
Response to letter: folate deficiency in Crohn's disease.
TL;DR: A significant proportion of patients with Crohn's disease suffer from folate deficiency, suggesting that regular screening should be performed.
Journal ArticleDOI
Switching to a Second Thiopurine in Adult and Elderly Patients With Inflammatory Bowel Disease: A Nationwide Study From the ENEIDA Registry
M Calafat,Míriam Mañosa,Francisco Mesonero,Jordi Guardiola,Miguel Minguez,Pilar Nos,Isabel Vera,Carlos Taxonera,Eva Iglesias,Elena Ricart,Javier P. Gisbert,Xavier Calvet,Santiago García-López,David Monfort,José Lázaro Pérez Calle,Sabino Riestra,Fernando Gomollón,Esther Garcia-Planella,Fernando Bermejo,Vicent Hernández,María Dolores Martín-Arranz,Ana Gutiérrez,Paola Torres,Fiorella Cañete,Eugeni Domènech +24 more
TL;DR: In a large series in clinical practice, switching to a second thiopurine proved to be a valid strategy and tight monitoring of elderly IBD patients switching to this strategy because of adverse events is recommended.